ONCS Announces Q4 and YTD Results for Fiscal 2015

Looks like they are moving:

"Finally, as a note of interest we are planning to move to a new well-equipped facility that will combine all of our clinical discovery research and administrative functions in one building before the [indiscernible]. Our new office school house state-of-the-art equipment to facilitate our immuno-oncology research efforts. We will provide more information on this exciting event as we get closer to our move-in date."

Unfortunate about the "inaudible" part. I imagine he said "before the [end of the year]"...? I'll have to listen if I can find where it's posted.

Per Dr. Mai Le, the patient enrollment numbers in current trials are as follows:

Melanoma Extended study: 20
Head & Neck: 3
Triple Negative breast: 0 (Pre-screening patients)
P2b combo: 8

8 is actually not bad. At that pace they'll be fully enrolled by next July. However, they should have 20 patients enrolled by end of January 2016, and could have at least 3 months worth of data on 10 or so patients by that time. That is if the current enrollment pace stays the same.

Upcoming milestones:

By year end

- Enroll first patient P2 triple - breast trial
- Enroll first 10 patients into P2b combo (already have enrolled 8)
- Move into new facility

Next 6 months (by mid-April 2016)

- Announce a new non-IL-12 lead candidate
- Announce new academic/industry collaboration

Next 12 months (by mid Oct. 2016)

- Present pre-clinical and biomarker data for P2b, Head & Neck, and triple - breast trials at key conferences
- Give updates on pre-clinical trials with collaborators (Heat and Plexxikon?)
- Continued R&D pipeline expansion

I think we can agree that PD has said many things over the years he should not have said.
I always gave him slack and mostly defended him, but my patience with him is running low.

Basically I cannot see any milestones that are serious enough to support the share price

Too many posts to respond to.
They are supposed to move into the new facility this month

8 patients in 3 months is not bad, first 30% of all applicants won't be accepted because they will be high TIL patients.  2nd the trial is at 1 facility that is also running T-Vec/Keytruda trial, so there will be some decision making as to which patients are better candidates for each trial.  3rd, trials for small companies tend to enroll slower.

Melanoma trial having 20 enrolled.  I thought there was supposed to be more.  I wonder if they decreased how many they were going to do because clinicaltrials.gov says this trial will be finished in Dec. 

I seriously doubt we get any info about the P2B trial this year, even if a patient responds they have to have 6 months of treatment before their treatment is finished, which means final data on patient 1 will be collected in Jan.  Punit being young and enthusiastic tends to over promise on timeline issues, that and his inability to speak publicly are the only 2 weakness I see him having.  His earlier statements of data this year were based on the trial starting in 2h

I agree in part with Belgium, I see nothing this year that supports the share price and see this sitting at or around $4 for the remainder of the year.  However 1h next year should see a massive appreciation in shareholder wealth. 

furbush,

Agreed.  The inclusion criteria (only choosing low TIL patients) is the reason why I am not surprised or disappointed that only 8 patients have enrolled so far.  I noticed that about the extended trial.  The clinicaltrials page was last updated on August 19th, 2015, which means they could have pushed back the trial completion date (final data collection date) if they wanted to.  They didn't, which in my opinion means they are content on the amount of patients they have to this point and not worried about enrolling 51, as stated.  Just to be sure, I sent an email to Dr. Le to ask about this.

I don't think we are going to get any official data on any of these new trials by years end.  It is listed on the "in the next 12 months" milestone list, not " by year end" or "next 6 months".  Since it is open label, I won't be surprised though if we hear bits and pieces of information about how enrollment is going, and if they are seeing encouraging results to this point etc...

I don't think that there are many major pps moving catalysts before years end, but I do think this thing has been beaten down big time.  I am buying now because I don't mind holding for the long haul (12 months) with such a low cost average.  It is stupid low at the moment in my opinion..although I said the same thing when it was at a $90M market cap